Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide.

Molecular cancer therapeutics - 1 Oct 2004

Jiang Xiuxian, Zhao Baoguang, Britton Robert, Lim Lynette Y, Leong Dan, Sanghera Jasbinder S, Zhou Bin-Bing S, Piers Edward, Andersen Raymond J, Roberge Michel

Abstract excerpt

Inhibitors of the G(2) DNA damage checkpoint can selectively sensitize cancer cells with mutated p53 to killing by DNA-damaging agents. Isogranulatimide is a G(2) checkpoint inhibitor containing a unique indole/maleimide/imidazole skeleton identified in a phenotypic cell-based screen; however, the mechanism of action of isogranulatimide is unknown. Using natural and synthetic isogranulatimide analogues, we show...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Checkpoint Kinase 1
Share to G2 Phase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glutamine

Share to Glycogen Synthase Kinase 3

Share to Glycogen Synthase Kinase 3 beta

Share to Inhibitory Concentration 50

Share to Maleimides

Share to Protein Kinase C beta

Source

Identifiers

PMID: 15486189

Genes

UCN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide.PMID 15486189Read ↗

Novel Checkpoint 1 InhibitorsSemantic proximity Read ↗

Chk1 Inhibitors for Novel Cancer TreatmentSemantic proximity Read ↗

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1Semantic proximity Read ↗

Radioprotection by hymenialdisine-derived checkpoint kinase 2 inhibitors.Semantic proximity Read ↗

Checkpoint kinase inhibitors: a review of the patent literatureSemantic proximity Read ↗

Unleashing Chk1 in cancer therapySemantic proximity Read ↗

Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancerSemantic proximity Read ↗

Identification of a checkpoint modulator with synthetic lethality to p53 mutants.Semantic proximity Read ↗

Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint.Semantic proximity Read ↗

Inhibition of Chk1 by CEP-3891 Accelerates Mitotic Nuclear Fragmentation in Response to Ionizing RadiationSemantic proximity Read ↗

A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01.Semantic proximity Read ↗

New Natural Compound Inhibitors of Checkpoint Kinase-1(CHK1) Based on Computational StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.